This may explain interstitial pneumonia in myelofibrosis and how treatment with JAK2 inhibitors to block the IL-6-mediated JAK2 downstream signaling pathway also blocked the final inflammatory reaction in the lung. The gene discussed is JAK2; the disease is myelofibrosis.